Denosumab (Prolia): How It Works, Benefits and Side Effects

What is denosumab (Prolia), and how does it work?

Denosumab is a medicine for osteoporosis given as an injection, and it works by blocking the cells that break bone down. The Royal Osteoporosis Society explains that denosumab "works by blocking the formation and activity of cells that break down bone" Royal Osteoporosis Society. More precisely, it is a human monoclonal (IgG2) antibody that targets a signalling protein called RANKL; by binding RANKL it stops the bone-removing cells (osteoclasts) from forming and working, which reduces bone breakdown Prolia SmPC (emc).

This is a genuinely different mechanism from the bisphosphonate tablets many people know. Bisphosphonates such as alendronic acid bind into the bone mineral itself and linger there, which is why treatment is reviewed after several years and a "drug holiday" can sometimes follow. Denosumab does not lock into the skeleton — it circulates, does its job, and then, in the words of the Royal Osteoporosis Society, "wears off quickly" once you stop Royal Osteoporosis Society. That single fact shapes almost everything else about how the drug is used. It treats the imbalance behind what causes osteoporosis rather than the underlying cause, so it works only for as long as it is kept up.

One quick point of confusion worth clearing up: denosumab is sold under two brand names. Prolia is the 60mg, six-monthly injection for osteoporosis and is what this article covers. Xgeva is a higher-dose form of the same drug used in cancer care to protect bone — a different dose and a different purpose.

How is denosumab given?

Denosumab for osteoporosis is given as a single 60mg injection under the skin once every six months, usually by a nurse or doctor at your GP surgery or hospital. The recommended dose in the product information is "60 mg denosumab administered as a single subcutaneous injection once every 6 months" Prolia SmPC (emc), and the Royal Osteoporosis Society confirms you "have an injection every six months, usually at the hospital or GP surgery" Royal Osteoporosis Society.

The injection goes into the tummy, the top of the thigh or the upper arm, and the needle is thin — most people report feeling very little Royal Osteoporosis Society. There are no fiddly rules about staying upright or taking it on an empty stomach, as there are with the tablets — but the trade-off is that keeping to the six-monthly schedule matters far more (see the section on stopping, below).

Who is denosumab suitable for?

Denosumab is licensed for postmenopausal women and for men with osteoporosis, or with a high enough risk of breaking a bone. The Royal Osteoporosis Society notes it "may be suitable if you have osteoporosis, or if your risk of breaking a bone is high enough," and that it "is licensed for use in women who have been through the menopause, and for men" Royal Osteoporosis Society. For postmenopausal women specifically, NICE (TA204) recommends denosumab as an option for those who cannot take or tolerate the oral bisphosphonates such as alendronate and whose fracture risk is high enough NICE TA204; NHS access for men is via the drug's licence and local arrangements rather than TA204. Your own suitability depends on your fracture risk, which is often estimated with a tool like FRAX — our guide to fracture risk and FRAX explains how that works.

One requirement applies before you start: your calcium needs to be in order. Adequate calcium and vitamin D "is important in all patients," and any existing low calcium "must be corrected by adequate intake of calcium and vitamin D before initiating therapy" Prolia SmPC (emc). Most people on denosumab are advised to take calcium and vitamin D alongside it.

What are the benefits of denosumab?

Denosumab reduces the risk of the fractures that matter most in osteoporosis — spine, hip and others. The product information states that "in postmenopausal women Prolia significantly reduces the risk of vertebral, non-vertebral and hip fractures" Prolia SmPC (emc), and the Royal Osteoporosis Society similarly says it "can help to make your bones stronger and reduce your risk of broken bones, including hip and spinal fractures" Royal Osteoporosis Society. Because it is an injection rather than a daily or weekly tablet with an empty-stomach routine, some people also find it easier to keep up with — an important factor when a treatment only helps for as long as it is taken.

What are the common side effects of denosumab?

Most people have no problems, and the common side effects tend to be aches and everyday infections rather than anything dramatic. The Royal Osteoporosis Society puts it plainly: "most people on denosumab don't have any problems" Royal Osteoporosis Society.

Where side effects do occur, the product information lists the most frequent ones. Pain in an arm or leg and general muscle-and-bone (musculoskeletal) pain are the "very common" reactions, while urinary and upper respiratory tract infections, sciatica, constipation, abdominal discomfort, and skin problems such as rash or eczema are listed as "common" Prolia SmPC (emc). The Royal Osteoporosis Society also flags severe skin infection as an uncommon effect, occurring in fewer than 1 in 100 people Royal Osteoporosis Society. If something is bothering you, your GP or nurse can advise — but, as the next section explains, denosumab is not a drug to abandon on your own.

What are the rare but serious side effects?

Denosumab can occasionally cause more serious problems — low blood calcium, jaw and thigh-bone complications — but these are genuinely rare. The Royal Osteoporosis Society lists three, each affecting fewer than 1 in 1,000 people taking denosumab Royal Osteoporosis Society:

• Low blood calcium (hypocalcaemia). This is why calcium and vitamin D matter, and why any low calcium is corrected before you start; the risk is higher in people with kidney problems.
• Osteonecrosis of the jaw (ONJ). Delayed healing inside the mouth, usually after dental work — the same rare effect associated with bisphosphonates. Keeping your teeth and gums healthy and telling your dentist you are on denosumab are the main safeguards.
• Atypical (unusual) thigh-bone fracture. A rare break in the thigh bone; new, unexplained thigh or groin pain should prompt a doctor's appointment.

These sit at the far, uncommon end of the picture, and for people at real risk of osteoporotic fractures the protection denosumab offers generally outweighs them. The one thing that is genuinely different — and more important — with denosumab is what happens when treatment stops.

Why can't you just stop denosumab? The rebound effect

This is the single most important thing to understand about denosumab: you cannot simply stop it, because stopping — or even substantially delaying — a dose can trigger a rapid "rebound" that raises the risk of multiple spinal fractures. The Royal Osteoporosis Society is explicit: "some people have had several spinal fractures in the following months after they've stopped denosumab. This is known as the 'rebound effect'" Royal Osteoporosis Society. Because the drug "wears off quickly," bone breakdown surges back and the density gained can be lost fast Royal Osteoporosis Society.

UK regulators have issued a formal warning on exactly this. The MHRA reports that an "increased risk of multiple vertebral fractures has been reported in patients within 18 months of stopping or delaying ongoing denosumab 60mg treatment" — some within the first 9 months — and advises that "patients should not stop denosumab without specialist review," with any missed dose given as soon as possible MHRA Drug Safety Update, 2020.

The practical upshot is that stopping denosumab is a managed process, not a decision to make alone. If treatment is to end, another drug is needed to "lock in" the benefit — the Royal Osteoporosis Society says people usually "change to a different drug treatment – usually a type of drug called a bisphosphonate," and that this needs to be arranged "around the time you were due to have your denosumab injection," with "an arrangement with your doctor to make sure you get the other drug treatment in time" Royal Osteoporosis Society. That follow-on bisphosphonate is often the same kind of medicine as alendronic acid.

How do you know denosumab is working?

You cannot feel your bones changing, so the only way to know whether denosumab is holding your bone density — and to inform the eventual decision to continue, stop or switch — is to measure it. Because a stop-or-switch decision hinges on where your bone density actually stands, being able to track it across treatment is genuinely useful.

That monitoring role is where a radiation-free approach fits. Standard DEXA uses a small X-ray dose; REMS (Radiofrequency Echographic Multi Spectrometry) is radiation-free, so it can be repeated safely to follow change over a course of treatment. It complements — rather than replaces — your GP's or specialist's plan and any decision about staying on denosumab or arranging a follow-on. If you are wondering how much bone can be regained, our guide to whether osteoporosis can be reversed is a useful read. You can also book a radiation-free bone health assessment or learn more about our bone health assessment.

---

This article is for general information and is not a substitute for advice from your GP, nurse or specialist — never start, stop or change a prescribed medicine, or delay a denosumab dose, on your own. It is part of our bone health series; to understand the bigger picture, see what causes osteoporosis.